Optimizing Basal Insulin Dosing - 21/11/19

| R.L. has consulted for GlySens Incorporated and Abbott Diabetes Care and has research support from the Stanford Maternal Child Health Research Institute and National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK007217, 1K12DK122550). D.M. has consulted for Abbott, the Helmsley Charitable Trust, Sanofi, Eli Lilly and has served on an advisory board for Insulet; has research support from the National Institutes of Health (including P30 DK116074 and 1K12DK122550), Juvenile Diabetes Research Foundation, and the Helmsley Charitable Trust; and his institution has research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, and Roche. D.M. is a member of the Editorial Board of The Journal of Pediatrics. |
Vol 215
P. 7-8 - décembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
